Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STAA Stock Forecast 2026-2027
$28.37
Current Price
$1.41B
Market Cap
Buy 3
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to STAA Price Targets
+41.0%
To High Target of $40.00
+2.2%
To Median Target of $29.00
-18.9%
To Low Target of $23.00
STAA Price Momentum
-5.3%
1 Week Change
-11.5%
1 Month Change
+66.1%
1 Year Change
+22.9%
Year-to-Date Change
-20.9%
From 52W High of $35.87
+82.0%
From 52W Low of $15.59
📊 TOP ANALYST CALLS
Did STAA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if STAAR Surgical is one of their latest high-conviction picks.
Latest STAA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, STAA has a neutral consensus with a median price target of $29.00 (ranging from $23.00 to $40.00). The overall analyst rating is Buy (7.1/10). Currently trading at $28.37, the median forecast implies a 2.2% upside. This outlook is supported by 3 Buy, 8 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Piccolo at Wedbush, projecting a 41.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STAA Analyst Ratings
3
Buy
8
Hold
0
Sell
STAA Price Target Range
Low
$23.00
Average
$29.00
High
$40.00
Current: $28.37
Latest STAA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STAA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 29, 2026 | Wedbush | Michael Piccolo | Outperform | Reiterates | $40.00 |
| May 15, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| May 14, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 14, 2026 | Piper Sandler | Neutral | Maintains | $N/A | |
| May 14, 2026 | Stifel | Hold | Maintains | $N/A | |
| May 14, 2026 | Wedbush | Outperform | Upgrade | $N/A | |
| May 14, 2026 | Mizuho | Neutral | Maintains | $N/A | |
| Apr 9, 2026 | Wedbush | Neutral | Maintains | $N/A | |
| Apr 9, 2026 | Canaccord Genuity | Buy | Upgrade | $N/A | |
| Mar 5, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Mar 4, 2026 | Stifel | Hold | Maintains | $N/A | |
| Feb 9, 2026 | Stifel | Hold | Maintains | $N/A | |
| Feb 3, 2026 | Wedbush | Neutral | Initiates | $N/A | |
| Jan 28, 2026 | Jefferies | Buy | Maintains | $N/A | |
| Jan 16, 2026 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Dec 10, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Dec 10, 2025 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Aug 7, 2025 | Stifel | Hold | Downgrade | $N/A | |
| Aug 6, 2025 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Aug 5, 2025 | Sidoti & Co. | Neutral | Downgrade | $N/A |
Staar Surgical Company (STAA) Competitors
The following stocks are similar to STAAR Surgical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Staar Surgical Company (STAA) Financial Data
Staar Surgical Company has a market capitalization of $1.41B with a P/E ratio of 49.7x. The company generates $290.38M in trailing twelve-month revenue with a -7.2% profit margin.
Revenue growth is +119.6% quarter-over-quarter, while maintaining an operating margin of +18.7% and return on equity of -6.0%.
Valuation Metrics
Market Cap
$1.41B
Enterprise Value
$1.29B
P/E Ratio
49.7x
PEG Ratio
-0.5x
Price/Sales
4.9x
Growth & Margins
Revenue Growth (YoY)
+119.6%
Gross Margin
+73.6%
Operating Margin
+18.7%
Net Margin
-7.2%
EPS Growth
+119.6%
Financial Health
Cash/Price Ratio
+11.6%
Current Ratio
5.1x
Debt/Equity
10.6x
ROE
-6.0%
ROA
+0.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Staar Surgical Company (STAA) Business Model
About Staar Surgical Company
What They Do
Designs and sells implantable lenses for eye surgery.
Business Model
Staar Surgical generates revenue primarily through the sale of its implantable lenses, specifically Implantable Collamer lenses used in refractive surgery and intraocular lenses for cataract surgery. The company markets these products to ophthalmic surgeons and surgical centers, leveraging specialized delivery systems for surgical applications.
Additional Information
Founded in 1982 and based in Lake Forest, California, Staar Surgical has performed over 2.5 million lens implants globally, establishing a strong presence in the ophthalmic medical devices sector.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,157
CEO
Mr. Stephen C. Farrell CFA
Country
United States
IPO Year
1992
Website
www.staar.comStaar Surgical Company (STAA) Latest News & Analysis
Latest News
Quick Summary
STAAR Surgical Company (STAA) highlights the unique features of its EVO ICL technology and discusses current market trends in refractive surgery.
Why It Matters
The discussion on EVO ICL technology highlights STAAR Surgical's competitive edge and market positioning, which could influence stock performance and investor confidence in the refractive surgery sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
STAAR Surgical (NASDAQ: STAA) will participate in the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, involving meetings and a webcast. Attendance is by invitation only.
Why It Matters
STAAR Surgical's participation in key conferences signals ongoing engagement with investors, potentially boosting confidence and interest in its innovative vision correction products.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
STAAR Surgical Company reported a 119% YoY revenue increase to $93.5M in Q1 2026, with a net income of $5.2M. Strong growth is driven by China's market rebound and improved operational efficiency.
Why It Matters
STAAR Surgical's strong revenue growth and profitability indicate robust demand and operational efficiency, enhancing its competitive position in the refractive surgery market and attracting investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Staar Surgical shares surged after the company exceeded first-quarter profit expectations, indicating strong financial performance.
Why It Matters
Staar Surgical's strong earnings signal robust demand and operational efficiency, potentially boosting investor confidence and driving share prices higher.
Source: Investors Business Daily
Market Sentiment:
Negative
STAAR Surgical Q1 Earnings Call Highlights
1 month ago
Quick Summary
STAAR Surgical (NASDAQ: STAA) reported a strong rebound in Q1 2026, with increased sales and profitability due to high demand in China, U.S. growth, and improved cost controls.
Why It Matters
STAAR Surgical's rebound in sales and profitability signals strong recovery potential and effective management strategies, making it a more attractive investment opportunity.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
STAAR Surgical Company (STAA) held its Q1 2026 earnings call, discussing financial performance and future outlook. Further details on revenue and projections were provided during the call.
Why It Matters
The Q1 2026 earnings call for STAAR Surgical provides insights into the company's financial health, growth prospects, and market performance, influencing investment decisions and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About STAA Stock
What is Staar Surgical Company's (STAA) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Staar Surgical Company (STAA) has a median price target of $29.00. The highest price target is $40.00 and the lowest is $23.00.
Is STAA stock a good investment in 2026?
According to current analyst ratings, STAA has 3 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $28.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STAA stock?
Wall Street analysts predict STAA stock could reach $29.00 in the next 12 months. This represents a 2.2% increase from the current price of $28.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Staar Surgical Company's business model?
Staar Surgical generates revenue primarily through the sale of its implantable lenses, specifically Implantable Collamer lenses used in refractive surgery and intraocular lenses for cataract surgery. The company markets these products to ophthalmic surgeons and surgical centers, leveraging specialized delivery systems for surgical applications.
What is the highest forecasted price for STAA Staar Surgical Company?
The highest price target for STAA is $40.00 from Michael Piccolo at Wedbush, which represents a 41.0% increase from the current price of $28.37.
What is the lowest forecasted price for STAA Staar Surgical Company?
The lowest price target for STAA is $23.00 from at , which represents a -18.9% decrease from the current price of $28.37.
What is the overall STAA consensus from analysts for Staar Surgical Company?
The overall analyst consensus for STAA is neutral. Out of 3 Wall Street analysts, 3 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $29.00.
How accurate are STAA stock price projections?
Stock price projections, including those for Staar Surgical Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 3:58 AM UTC